Corvus Pharmaceuticals, Inc.
CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITKā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$13.37
Price+0.83%
$0.11
1Y
Price
Market Cap
$1.124b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$44.168m
-189.0%
1y CAGR-81.3%
3y CAGR-52.4%
5y CAGREPS
-$0.55
-3.8%
1y CAGR-12.6%
3y CAGR-0.2%
5y CAGRBook Value
$240.679m
$253.195m
Assets$12.516m
Liabilities$834k
DebtDebt to Assets
0.3%
-
Debt to EBITDAFree Cash Flow
-$35.137m
-6.6%
1y CAGR-14.1%
3y CAGR-7.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company